Search Results - "Paz, Hildegarde"

Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD by Pinto-Plata, Victor, Casanova, Ciro, Müllerova, Hana, de Torres, Juan P, Corado, Henneth, Varo, Nerea, Cordoba, Elizabeth, Zeineldine, Salah, Paz, Hildegarde, Baz, Rebeca, Divo, Miguel, Cortopassi, Felipe, Celli, Bartolome R

“…The relationship between serum biomarkers and clinical expressions of COPD is limited. We planned to further describe this association using markers of…”
Get full text

Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD by Paz-Díaz, Hildegarde, Montes de Oca, Maria, López, Jose M, Celli, Bartolome R

“…To determine the impact of an 8-wk program of comprehensive pulmonary rehabilitation on depression, anxiety, dyspnea, and health-related quality of life in…”
Get full text

Poster 27: Free Fat Mass Helps Predict Exercise Capacity Better Than Weight During Cardiopulmonary Exercise Test in Normal Subjects by Paz-Diaz, Hildegarde, MD, Toor, Harpreet, MD, Celli, Bartolome, MD, Pinto-Plata, Victor, MD

Get full text

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR by Rayment, Jonathan H, Asfour, Fadi, Rosenfeld, Margaret, Higgins, Mark, Liu, Lingyun, Mascia, Molly, Paz-Diaz, Hildegarde, Tian, Simon, Zahigian, Rachel, McColley, Susanna A

“…Previous phase 3 trials showed that treatment with lumacaftor/ivacaftor was safe and efficacious in people aged ⩾2 years with cystic fibrosis (CF) homozygous…”
Get full text

Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial by Flume, Patrick A., Harris, R. Scott, Paz-Diaz, Hildegarde, Ahluwalia, Neil, Higgins, Mark, Campbell, Daniel, Berhane, Indrias, Shih, Judy L., Sawicki, Gregory

“…•In Study 661-110 of TEZ/IVA in pwCF and the F508del-CFTR mutation:•pwCF aged ≥12 years completed 96 additional weeks of treatment, totaling…”
Get full text

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study by Flume, Patrick A, Downey, Damian G, Brown, Cynthia, Fischer, Rainald, De Boeck, Kris, Chang, Philip, Rubin, Jaime L, Yang, Yoojung, Wang, Xin, Ahluwalia, Neil, Owen, Caroline A, Ahrens, Richard C., Aitken, Moira, McBennett, Kimberly Ann, Pilewski, Joseph M., Billings, Joanne, Linnemann, Rachel, Powers, Michael R., Frederick, Carla Anne, Black, Philip, Berdella, Maria, Brown, Cynthia D., Anstead, Michael, Sicilian, Leonard, Moffett, Kathryn, Nasr, Samya, Taylor-Cousar, Jennifer, Barto, Tara Lynn, Antos, Nicholas, Quick, Bryon, Thompson, Henry R., Sawicki, Gregory, Smith, Thomas C., Schultz, Karen D., Omlor, Gregory J., Mehdi, Nighat, Ortiz, Maria Gabriela Tupayachi, Gardner, Tonia E., Jain, Raksha, Berlinski, Ariel, Calimano, Francisco J., Lascano, Jorge E., McWilliams, Bennie, Morrissey, Brian, Chittivelu, Subramanyam, Klingsberg, Ross, Biller, Julie A., Bui, Stephanie, Sommerburg, Olaf, Bignamini, Elisabetta, Collura, Mirella, Bentur, Lea, Efrati, Ori, Gallego, Esther Quintana, Barry, Peter, Asensi, Jose Ramon Villa, Armstrong, David Stuart, de la Cruz, Oscar Asensio, Gilchrist, Francis, Lands, Larry C., Lavoie, Annick, Linnane, Barry, Elidemir, Okan, Ringshausen, Felix, Kappler, Matthias, Hebestreit, Helge, Mainz, Jochen, Staab, Doris, Gleiber, Wolfgang, Pressler, Tacjana, Ketchell, Robert Ian, Doe, Simon, Nash, Edward Fairbairn, Peckham, Daniel Gavin, Kansra, Sonal, Delaisi, Bertrand, Le Bihan, Jean, Fajac, Isabelle, Sermet-Gaudelus, Isabelle, De Boeck, Christiane, Reix, Philippe, van Braeckel, Eva, Prevotat, Anne, van der Meer, Renske, Weersink, E.J.M., Gartner, Silvia, Jover, Amparo Sole, Fernandez, Antonio Alvarez, Cox, Desmond William, McKone, Edward F., Bowler, Simon David, Wainwright, Claire Elizabeth, Wilson, John William, Volpi, Sonia, Colombo, Carla, Fabrizzi, Benedetta, Lucidi, Vincenzina, Cucchiara, Salvatore, Eber, Ernst, Krantz, Christina

“…Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well…”
Get full text

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant by Sawicki, Gregory S., Chilvers, Mark, McNamara, John, Naehrlich, Lutz, Saunders, Clare, Sermet-Gaudelus, Isabelle, Wainwright, Claire E., Ahluwalia, Neil, Campbell, Daniel, Harris, R. Scott, Paz-Diaz, Hildegarde, Shih, Judy L., Davies, Jane C.

“…•In a phase 3 extension study of children ≥ 6 years with CF and F/F or F/RF genotypes:•TEZ/IVA was safe and well tolerated over 96 weeks, with no new safety…”
Get full text